A detailed history of Geode Capital Management, LLC transactions in Altimmune, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 1,668,004 shares of ALT stock, worth $12.9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,668,004
Previous 1,593,810 4.66%
Holding current value
$12.9 Million
Previous $10.6 Million 3.37%
% of portfolio
0.0%
Previous 0.0%

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$5.5 - $8.1 $408,067 - $600,971
74,194 Added 4.66%
1,668,004 $10.2 Million
Q2 2024

Aug 09, 2024

BUY
$5.91 - $10.23 $2.11 Million - $3.65 Million
357,012 Added 28.87%
1,593,810 $10.6 Million
Q1 2024

May 13, 2024

BUY
$8.22 - $13.81 $355,679 - $597,558
43,270 Added 3.63%
1,236,798 $12.6 Million
Q4 2023

Feb 13, 2024

BUY
$2.14 - $11.62 $300,010 - $1.63 Million
140,192 Added 13.31%
1,193,528 $13.4 Million
Q3 2023

Nov 13, 2023

BUY
$2.4 - $3.45 $200,340 - $287,988
83,475 Added 8.61%
1,053,336 $2.74 Million
Q2 2023

Aug 11, 2023

BUY
$3.45 - $5.97 $1.68 Million - $2.91 Million
487,500 Added 101.07%
969,861 $3.42 Million
Q1 2023

May 15, 2023

BUY
$4.19 - $16.83 $182,177 - $731,751
43,479 Added 9.91%
482,361 $2.04 Million
Q4 2022

Feb 13, 2023

SELL
$8.74 - $16.45 $324,996 - $611,693
-37,185 Reduced 7.81%
438,882 $7.22 Million
Q3 2022

Nov 14, 2022

BUY
$10.67 - $22.41 $1.03 Million - $2.16 Million
96,236 Added 25.34%
476,067 $6.08 Million
Q2 2022

Aug 12, 2022

SELL
$3.94 - $11.77 $1.03 Million - $3.08 Million
-261,990 Reduced 40.82%
379,831 $4.44 Million
Q1 2022

May 13, 2022

BUY
$5.9 - $9.45 $51,784 - $82,942
8,777 Added 1.39%
641,821 $3.91 Million
Q4 2021

Feb 11, 2022

SELL
$8.69 - $12.48 $224,271 - $322,083
-25,808 Reduced 3.92%
633,044 $5.8 Million
Q3 2021

Nov 12, 2021

BUY
$8.43 - $16.81 $1.04 Million - $2.07 Million
123,336 Added 23.03%
658,852 $7.45 Million
Q2 2021

Aug 13, 2021

BUY
$9.85 - $16.46 $2.82 Million - $4.71 Million
286,386 Added 114.95%
535,516 $5.27 Million
Q1 2021

May 12, 2021

BUY
$12.71 - $24.31 $646,583 - $1.24 Million
50,872 Added 25.66%
249,130 $3.52 Million
Q4 2020

Feb 12, 2021

BUY
$7.84 - $14.22 $146,506 - $265,729
18,687 Added 10.41%
198,258 $2.24 Million
Q3 2020

Nov 13, 2020

BUY
$9.93 - $33.26 $899,032 - $3.01 Million
90,537 Added 101.69%
179,571 $2.37 Million
Q2 2020

Aug 13, 2020

BUY
$2.9 - $10.71 $8,291 - $30,619
2,859 Added 3.32%
89,034 $953,000
Q3 2019

Nov 12, 2019

BUY
$1.95 - $2.66 $2,646 - $3,609
1,357 Added 1.6%
86,175 $168,000
Q2 2019

Aug 14, 2019

BUY
$2.19 - $3.4 $78,060 - $121,189
35,644 Added 72.49%
84,818 $201,000
Q1 2019

May 14, 2019

BUY
$2.54 - $4.54 $83,977 - $150,101
33,062 Added 205.2%
49,174 $142,000
Q4 2018

Feb 13, 2019

BUY
$1.72 - $7.24 $27,712 - $116,650
16,112 New
16,112 $33,000

Others Institutions Holding ALT

About Altimmune, Inc.


  • Ticker ALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,025,300
  • Market Cap $380M
  • Description
  • Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...
More about ALT
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.